Semaglutide Use Linked to Erythromelalgia Remission

• by Kathryn Wighton

• April 22, 2026

FDA approves oral dermatomyositis therapy

Phase 3 findings show improvements in physical function and skin disease activity.

• by Kathryn Wighton

• August 28, 2026

• 2 min

Rare Skin Reaction Reported With Tirzepatide

A single case report described possible lichen planus pigmentosus inversus following tirzepatide initiation.

• by Andrea Surnit

• May 7, 2026

• 3 min

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

• by Kerri Miller

• April 17, 2026

• 6 min